Business Description
Argent Biopharma Ltd
ISIN : AU0000326647
Compare
Compare
Traded in other countries / regions
RGT.AustraliaH5O0.GermanyRGTLF.USA IPO Date
2006-12-21Description
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | -4.2 | |||||
Debt-to-Equity | -1.06 | |||||
Debt-to-EBITDA | -1.08 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -111.29 | |||||
Beneish M-Score | -16.15 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -82.4 | |||||
3-Year EBITDA Growth Rate | 64.3 | |||||
3-Year EPS without NRI Growth Rate | 61.4 | |||||
3-Year FCF Growth Rate | 69.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.84 | |||||
9-Day RSI | 49.85 | |||||
14-Day RSI | 48.79 | |||||
3-1 Month Momentum % | -13.95 | |||||
6-1 Month Momentum % | -47.14 | |||||
12-1 Month Momentum % | -54.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.21 | |||||
Quick Ratio | 0.21 | |||||
Cash Ratio | 0.17 | |||||
Days Inventory | 478.44 | |||||
Days Sales Outstanding | 196.61 | |||||
Days Payable | 2836.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -204.1 | |||||
Shareholder Yield % | -233.61 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 15.21 | |||||
Operating Margin % | -1871.57 | |||||
Net Margin % | -2149.13 | |||||
EBITDA Margin % | -2052.87 | |||||
FCF Margin % | -1898.5 | |||||
OCF Margin % | -1898 | |||||
ROA % | -343.03 | |||||
ROIC % | -87.37 | |||||
3-Year ROIIC % | 9.18 | |||||
ROC (Joel Greenblatt) % | -1635.39 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.17 | |||||
EV-to-EBIT | -1.34 | |||||
EV-to-EBITDA | -1.4 | |||||
EV-to-Forward-EBITDA | 404.98 | |||||
EV-to-Revenue | 28.66 | |||||
EV-to-Forward-Revenue | 1.93 | |||||
EV-to-FCF | -1.51 | |||||
Price-to-GF-Value | 1.23 | |||||
Earnings Yield (Greenblatt) % | -74.63 | |||||
FCF Yield % | -185.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Argent Biopharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 0.401 | ||
| EPS (TTM) (A$) | -0.111 | ||
| Beta | 0.2641 | ||
| 3-Year Sharpe Ratio | -1.57 | ||
| 3-Year Sortino Ratio | -1.72 | ||
| Volatility % | 85.7 | ||
| 14-Day RSI | 48.79 | ||
| 14-Day ATR (A$) | 0.000907 | ||
| 20-Day SMA (A$) | 0.0368 | ||
| 12-1 Month Momentum % | -54.88 | ||
| 52-Week Range (A$) | 0.033 - 0.32 | ||
| Shares Outstanding (Mil) | 111.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Argent Biopharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Argent Biopharma Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-02-27 | 0.06 (+0.00%) | ||
| General meeting for 2025 | 2025-11-28 16:00 | 0.08 (+5.26%) | ||
| Annual report for 2025 | 2025-09-30 | 0.10 (-2.04%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 0.14 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-02-28 | 0.14 (+0.00%) | ||
| General meeting for 2024 | 2024-11-28 16:00 | 0.25 (-1.96%) | ||
| Annual report for 2024 | 2024-09-30 | 0.36 (+1.43%) | ||
| Fourth quarter earnings results for 2024 | 2024-08-30 | 0.33 (+3.13%) | ||
| 0.001:1 Stock Split | 2023-10-30 | 1.00 (+0.00%) | ||
| 0.1:1 Stock Split | 2012-08-21 | 187.50 (+0.00%) |
Show
Entries
Argent Biopharma Ltd Frequently Asked Questions
What is Argent Biopharma Ltd(ASX:RGT)'s stock price today?
The current price of ASX:RGT is A$0.04. The 52 week high of ASX:RGT is A$0.32 and 52 week low is A$0.03.
When is next earnings date of Argent Biopharma Ltd(ASX:RGT)?
The next earnings date of Argent Biopharma Ltd(ASX:RGT) is 2026-08-29 Est..
Does Argent Biopharma Ltd(ASX:RGT) pay dividends? If so, how much?
Argent Biopharma Ltd(ASX:RGT) does not pay dividend.
Press Release
Articles on Argent Biopharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers